Reparixin is an allosteric inhibitor of CXCR1 and CXCR2 that has been shown to inhibit neutrophil trafficking during ischemia–reperfusion injury and acid-induced acute lung injury (Bertini et al., 2004; Zarbock et al., 2008; Hosoki and Sur, 2018). Here, CXCR1 is linked to acute lung injury.